ArticleGynecology and minimally invasive therapy
The Impact of Gonadotropin-releasing Hormone Agonist Combined with Lauromacrogol on Ovarian Reserve Function and Pain Scores in Patients with Ovarian Endometriotic Cysts.
Article in Gynecology and minimally invasive therapy. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Minimally Invasive Innovation in Endometriosis and Adenomyosis: Toward Fertility Preservation and Symptom Relief.Gynecology and minimally invasive therapyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: To evaluate the efficacy of gonadotropin-releasing hormone agonist (GnRHa) combined with lauromacrogol sclerotherapy in preserving ovarian reserve and reducing pain in patients with ovarian endometriotic cysts (OECs). Materials and Methods: Eighty OEC patients (Oct 2020-Oct 2024) were randomized into two groups ( Results: The total effective rate of the observation group (95.00%, 95% CI: 87.2-98.9) was higher than that of the control group (77.50%, 95% CI: 65.1-86.8; OR=5.51, 95% CI: 1.21-15.56, Conclusion: The combination of GnRHa and lauromacrogol sclerotherapy has a significant effect on OEC, which can improve ovarian reserve function, reduce pain scores and recurrence rates.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.